Aging Global Population Will Boost HCM Therapy Uptake
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 19 Analysts
Published
10 Aug 25
Updated
10 Aug 25
AnalystHighTarget's Fair Value
US$112.91
66.5% undervalued intrinsic discount10 Aug
US$37.84
1Y
-33.4%7D
10.3%